These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26687450)

  • 1. Overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones.
    Glorieux C; Sandoval JM; Dejeans N; Ameye G; Poirel HA; Verrax J; Calderon PB
    Life Sci; 2016 Jan; 145():57-65. PubMed ID: 26687450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Cell Sensitivity to Redox-Cycling Quinones is Influenced by NAD(P)H: Quinone Oxidoreductase 1 Polymorphism.
    Glorieux C; Buc Calderon P
    Antioxidants (Basel); 2019 Sep; 8(9):. PubMed ID: 31480790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.
    Singh S; Zahid M; Saeed M; Gaikwad NW; Meza JL; Cavalieri EL; Rogan EG; Chakravarti D
    J Steroid Biochem Mol Biol; 2009 Oct; 117(1-3):56-66. PubMed ID: 19628038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
    Siegel D; Yan C; Ross D
    Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.
    Fagerholm R; Hofstetter B; Tommiska J; Aaltonen K; Vrtel R; Syrjäkoski K; Kallioniemi A; Kilpivaara O; Mannermaa A; Kosma VM; Uusitupa M; Eskelinen M; Kataja V; Aittomäki K; von Smitten K; Heikkilä P; Lukas J; Holli K; Bartkova J; Blomqvist C; Bartek J; Nevanlinna H
    Nat Genet; 2008 Jul; 40(7):844-53. PubMed ID: 18511948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
    Zhang K; Chen D; Ma K; Wu X; Hao H; Jiang S
    J Med Chem; 2018 Aug; 61(16):6983-7003. PubMed ID: 29712428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
    Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
    Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
    Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
    Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient NQO1 substrates are potent and selective anticancer agents.
    Parkinson EI; Bair JS; Cismesia M; Hergenrother PJ
    ACS Chem Biol; 2013 Oct; 8(10):2173-83. PubMed ID: 23937670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
    Colucci MA; Moody CJ; Couch GD
    Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
    Dehn DL; Winski SL; Ross D
    Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
    Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
    J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma.
    Cabello CM; Lamore SD; Bair WB; Davis AL; Azimian SM; Wondrak GT
    Free Radic Res; 2011 Mar; 45(3):276-92. PubMed ID: 21034357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
    Bian J; Deng B; Xu L; Xu X; Wang N; Hu T; Yao Z; Du J; Yang L; Lei Y; Li X; Sun H; Zhang X; You Q
    Eur J Med Chem; 2014 Jul; 82():56-67. PubMed ID: 24874653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
    Winski SL; Hargreaves RH; Butler J; Ross D
    Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression.
    Lin YL; Ho IC; Su PF; Lee TC
    Toxicol Appl Pharmacol; 2006 Aug; 214(3):309-17. PubMed ID: 16494910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
    Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
    Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased tumor necrosis factor-alpha sensitivity of MCF-7 cells transfected with NAD(P)H:quinone reductase.
    Siemankowski LM; Morreale J; Butts BD; Briehl MM
    Cancer Res; 2000 Jul; 60(13):3638-44. PubMed ID: 10910079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
    Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
    J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.
    Traver RD; Horikoshi T; Danenberg KD; Stadlbauer TH; Danenberg PV; Ross D; Gibson NW
    Cancer Res; 1992 Feb; 52(4):797-802. PubMed ID: 1737339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.